摘要
70例肺癌疗前新鲜标本，采用特异识别簇单克隆抗体C219，检测MDR1P-糖蛋白（MDR1P－glycoprotein，MDR1P－gp）表达与疗效、预后关系。结果示：MDR1P－gp（＋）率34％（24／70）；低分化鳞、腺癌与中及高分化型MDR1P－gp（＋）各为52％（13／25）及21％（6／29），差别显著（P＜0．05，x2=4．4802）；表达（＋）～者占96％（23／24），仅4．2％（1／24）（P=1×109）。表达程度与晚期无关；6例原发瘤与复发转移瘤间仅1例MDR1P－gp表达相符；32例接受化疗，MDR1P－gp与治疗符合率94％（30／32）：MDR1P－gp（＋）与治疗符合率75％，（－）则为61％（P＞0.05）。SCLC与治疗符合率100％（9／9），NSCLC为48％（12／23）（P=0．01），提示（MDR1P－gp表达可能能反映SCLC疗效；中数生存期（MSD）MDR1P－gp（＋）及（－）各为6．5月与13月（P=0.001）Kaplan-Meier曲线及Log-Randtest（P＜0．01x2=7．085）均提示MDR1P-gp（-）者有明显生存期优势。现存5例，（＋）组1例22+月，（－）组4例，48+月3例，37+月1例。故MDR1P－gp表达可能有预测预后意义。
Fresh untreated specimens fr0m 70 lung cancers were analysed for MDR1 P-glycoprotein (MDR1 P-gp ) with monoclonal antibody C219 by immunohistochemical staining assay to evaluate the relationshipbetween the expressions, therapeutic effect and prognosis. The overall MDR1 P-gp expression was observed in 34% (24/70). After compared the poorly differentiated squamous carcinomas and adenocarcinomas with theirmoderate and well differentiated types, the MDR1 P-gp expressi0n was 52 % (13/25) and 21 % (6/29) respectively (P<0. 05 X2= 4. 4802). 95 % of the tumorcells showed 10%-30% C219 staining, which indicated that the weak MDR1 P-gp expression was predominant in our patients.There was norelationship between MDR1 Pmgp expression and advanced TNM stages. Only17 % (1/6 ) of the patlents the MDR1 P-gp expression was consistent between the primary and metastatic tumors. Thirty-two patients received chemotherapy, agreement of therapeutic effect and MDR1 P-gp expression was seen in 66 % (21/32). The concordance rate of SCLC or NSCLC was 100% (9/9 )and 52 % (12/23 ) respectively (P = 0.004). It seems that MDR1 P-gp expression may reflect the therapeutic effect in SCLC. The median survival duration (MSD) in patients with MDR1 P-gp (+ ) or (- ) was 6. 5 mon ths and 13 months respectively (P=0. 02). The Kaplan-Meier's curves and log-rank test (P<0. 01 X2 = 7. 085)showed that survival of the patients with MDRl P-gp (- ) was much better than that with MDR1 P-gp (+ ) ones. Four patients with MDRl P-gp (- ) are still alive, three in their 38+ months, one in her 37+ months. Only one patient with MDR1 P-gp (+) is alive in his 22+ months. The data showed that MDR1 P-gp expression maybe a prognostic factor in untreated lung cancer patients.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1997年第11期805-810,共6页
Chinese Journal of Clinical Oncology
基金
国家"八五"攻关项目基金
关键词
肺肿瘤
MDR1P
糖蛋白
疗效
预后
Lung cancer Multidrug resistance Prognosis Remission rate
